Mahamaya Lifesc. (544611)

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 25.87% indicates efficient capital deployment
• Profit growth of 15.45% exceeds sales growth of 11.69%, suggesting margin improvement
• Piotroski F-Score of 7/9 reflects solid operational and financial health
• Latest quarter is profitable with ₹8 Cr net profit on ₹163 Cr sales

Concerns

• P/E of 26 and PEG of 1.92 make the valuation expensive relative to current growth
• No dividend yield, so returns rely entirely on capital appreciation
• Critical data missing — book value, debt/equity, ROE, and promoter holding — limits risk assessment
• Pesticides and agrochemicals are cyclical and competitive, with exposure to monsoon and regulatory risks

AI Analysis

Let me start with what I admire. Mahamaya Lifesc earns a 25.87% return on capital employed, a figure that would interest any investor. The latest quarter shows ₹163 crore of sales and ₹8 crore of net profit, a net margin of roughly 4.9%. Sales grew 11.69% and profit grew 15.45% — profit outpacing sales tells me margins are moving in the right direction. The Piotroski F-Score of 7 out of 9 also points to a reasonably sound financial position. That is genuine fundamental evidence. But Graham would remind me to demand a margin of safety. At ₹156.05, the market capitalisation is ₹365 crore, and with a P/E of 26, you are paying a full price for a company growing profits at 15.45%. The PEG ratio of 1.92 suggests the market has already embedded much of the near-term optimism. There is no dividend — zero — so the only return to shareholders must come from price appreciation and reinvested growth. That makes valuation discipline even more important. I cannot fully apply my checklist because key data are missing: book value, debt-to-equity, return on equity, and promoter holding are unavailable. Without a balance sheet, I cannot properly assess downside risk. In agrochemicals, cyclicality, regulatory changes, monsoon dependence, and competitive pressure are real threats. A strong return on capital in one quarter is not a durable moat. This may be a decent fast-growing small-cap, but at 26 times earnings and with incomplete data, I would wait for a better price or far more evidence.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer